Aumed, a.s., Komořanská 326/63, 143 14 Praha - Modřany, Česká republika

+420 603 587 701 English

AUMED, a.s. received support for the development of a vaccine against Staphylococcus aureus


AUMED received support for the project “Development of a new vaccine against Staphylococcus aureus”, registration number CZ.01.01.01/01/22_002/0000585.

Staphylococcus aureus causes a wide range of diseases from skin infections to life-threatening invasive diseases such as bacteremia, endocarditis, pneumonia, surgical site infections, osteomyelitis and secondary nosocomial staphylococcal infections that occur mainly in intensive care units (MRSA, burns, surgical departments, immunodeficient patients, patients with implants, etc.).

The bacterium S. aureus is one of 12 designated by the World Health Organization as a “priority pathogen” – meaning investment in new drugs is urgently needed – because it is increasingly resistant to antibiotics. With antibiotic resistance increasing dramatically, there is an intensive search for alternative treatments to antibiotic procedures on several levels. One level is the use of bacteriophages for the treatment of staphylococcal attacks or the possibility of using microbial genetic mutations.

Appropriate vaccination can be a real solution to this socially serious problem. However, developing a vaccine against Staphylococcus aureus is proving to be significantly more challenging than expected. So far, the traditional technique using surface antigens (capsular conjugates or protein) has been ineffective. The idea of a Czech vaccine against staphylococci is not entirely new. The vaccine with the trademark Polystafana already existed historically, was recently used and confirmed the reality of expectations. However, its production technology and forms of control did not meet the current legislative requirements and GMP (good manufacturing practice in pharmacy) requirements for the production of vaccines, therefore its production, registration and clinical use completely disappeared.

The aim of the project is the development of a vaccine against Staphylococcus aureus based on exogenous toxoids, as an effective component of the drug. The prepared vaccine does not use either cell antigens or cell wall proteins or a live attenuated microorganism, i.e. the usually preferred antigenic bases present in other vaccines developed against staphylococci, as antigenic components to induce a protective effect. In the procedure proposed by the project, the vaccine is innovative.

The project will receive financial support from the EU within the Operational Program Technologies and Applications for Competitiveness, Challenges Applications – Challenge I.


Aumed Pharma a.s. launches the new Phage Glow Skin Spray

04. 06. 2024

Our subsidiary Aumed Pharma a.s. launches a special bioactive gel intended for eczematous skin Phage Glow Skin Spray – a…

New workplace BENÁTKY n/J.

10. 05. 2024

AUMED, a.s. at the beginning of 2024 opened a new workplace at the address 5. května 301, 294 71 Benátky…

Aumed Pharma a.s. launches new food supplement Gut Guard

07. 03. 2024

Our subsidiary Aumed Pharma a.s. launches food supplement Gut Guard. Gut Guard probiotics contain a combination of 13 vital probiotic…

Research projects of Aumed, a.s. are financed by the European Structural Funds and with financial support from the state budget through the Ministry of Industry and Trade. A complete list of all ongoing and completed projects with this support can be found here.

European Union
European Regional Development Fund
OP Enterprise and Innovation for Competitiveness

Tel.: +420 603 587 701
Komořanská 326/63, 143 14 Praha - Modřany, Česká republika
(c) 2017, Aumed a.s